Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Enrolling By Invitation NCT06194799

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Conditions: Alzheimer's Disease Psychosis

Sex: All
Ages: 55 Years – 95 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 752
Sponsor: ACADIA Pharmaceuticals Inc.

Location: Clinical Endpoints LLC Scottsdale Arizona

Summary

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

Eligibility Criteria

Inclusion Criteria: * Subject has successfully completed ACP-204-006 study * Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential * Subject has a designated study partner/caregiver * Subjects are able to complete all study visits with a study partner/caregiver * Signed inform consent form with a caregiver or legal representative Exclusion Criteria: * Requires treatment with a medication prohibited by the protocol * Is in hospice and receiving end-of-life palliative care, or has become bedridden * Unstable clinically significant medical condition other than AD * Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06194799). StuddyBuddy aggregates publicly available trial information.